Merck Minus Medco Sets Ambitious Margin Benchmark: 82% On Pure Rx
Executive Summary
Merck's first post-Medco benchmark for the investment community is a reinvigorated pure pharma gross profit margin of 82%
You may also be interested in...
Medco IPO Delay: Merck Trades Gross Margin For Cloudy Rebate Calculations
Merck's gross margins would be about five percentage points higher if the company excluded copayments for Medco-managed prescriptions from its revenue line
Medco IPO Delay: Merck Trades Gross Margin For Cloudy Rebate Calculations
Merck's gross margins would be about five percentage points higher if the company excluded copayments for Medco-managed prescriptions from its revenue line
Zocor To Get Special Medco Attention: Market Share Protections Set In IPO
Merck's Zocor protection program for the spin-off of MedcoHealth Solutions includes an incentive for Medco to keep the cholesterol agent at a market share level tied to its 2001 position